NO307702B1 - Retinsyre-X-reseptorligander, anvendelse derav og farmasøytiske preparater - Google Patents

Retinsyre-X-reseptorligander, anvendelse derav og farmasøytiske preparater

Info

Publication number
NO307702B1
NO307702B1 NO970580A NO970580A NO307702B1 NO 307702 B1 NO307702 B1 NO 307702B1 NO 970580 A NO970580 A NO 970580A NO 970580 A NO970580 A NO 970580A NO 307702 B1 NO307702 B1 NO 307702B1
Authority
NO
Norway
Prior art keywords
pct
pharmaceutical compositions
retinoic acid
receptor ligands
sec
Prior art date
Application number
NO970580A
Other languages
English (en)
Norwegian (no)
Other versions
NO970580D0 (no
NO970580L (no
Inventor
Michael Klaus
Allen John Lovey
Peter Mohr
Michael Rosenberger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO970580D0 publication Critical patent/NO970580D0/no
Publication of NO970580L publication Critical patent/NO970580L/no
Publication of NO307702B1 publication Critical patent/NO307702B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/56—Crotonic acid esters; Vinyl acetic acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C07C45/298—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with manganese derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/24—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO970580A 1994-08-10 1997-02-07 Retinsyre-X-reseptorligander, anvendelse derav og farmasøytiske preparater NO307702B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94112461 1994-08-10
EP95110460 1995-07-05
PCT/EP1995/003021 WO1996005165A1 (en) 1994-08-10 1995-07-29 Retinoic acid x-receptor ligands

Publications (3)

Publication Number Publication Date
NO970580D0 NO970580D0 (no) 1997-02-07
NO970580L NO970580L (no) 1997-02-07
NO307702B1 true NO307702B1 (no) 2000-05-15

Family

ID=26135772

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970580A NO307702B1 (no) 1994-08-10 1997-02-07 Retinsyre-X-reseptorligander, anvendelse derav og farmasøytiske preparater

Country Status (24)

Country Link
US (1) US5801253A (cs)
EP (1) EP0775103B1 (cs)
JP (1) JP2848964B2 (cs)
KR (1) KR100363545B1 (cs)
CN (1) CN1091092C (cs)
AT (1) ATE181052T1 (cs)
AU (1) AU696501B2 (cs)
BR (1) BR9508985A (cs)
CA (1) CA2196197C (cs)
CY (1) CY2170B1 (cs)
CZ (1) CZ288526B6 (cs)
DE (1) DE69510203T2 (cs)
DK (1) DK0775103T3 (cs)
ES (1) ES2133798T3 (cs)
FI (1) FI112357B (cs)
GR (1) GR3031154T3 (cs)
HU (1) HU218268B (cs)
MX (1) MX9700778A (cs)
NO (1) NO307702B1 (cs)
NZ (1) NZ292121A (cs)
PL (1) PL180048B1 (cs)
RU (1) RU2146241C1 (cs)
TR (1) TR199500976A2 (cs)
WO (1) WO1996005165A1 (cs)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466861A (en) * 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
IL116259A (en) * 1994-12-19 2000-07-16 American Cyanamid Co Analogs of 9-cis retinoic acid and their use
US5968908A (en) * 1994-12-19 1999-10-19 American Cyanamid Company Restricted 9-cis retinoids
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US6942980B1 (en) 1995-09-01 2005-09-13 Allergan, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
CA2204616C (en) 1995-09-18 2002-12-17 Ranjan Mukherjee Ppar gamma antagonists for treating obesity
WO1997012853A1 (en) 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
FR2746101B1 (fr) * 1996-03-14 1998-04-30 Composes bicycliques-aromatiques
US5741896A (en) 1996-06-21 1998-04-21 Allergan O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
ATE265997T1 (de) * 1996-06-21 2004-05-15 Allergan Inc Substituierte tetrahydronaphthalin- und dihydronaphthalin-derivate mit einer retinoiden und/oder retinoid antagonist-ähnlichen biologischen aktivität
AU5601898A (en) 1996-12-11 1998-07-03 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumour cell growth
US5728846A (en) 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
AU8588798A (en) 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
CN1301156A (zh) * 1997-11-12 2001-06-27 弗·哈夫曼-拉罗切有限公司 2型t辅助细胞介导的免疫病的治疗
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
WO1999063980A1 (en) * 1998-06-12 1999-12-16 Ligand Pharmaceuticals Inc. Treatment of anti-estrogen resistant breast cancer using rxr modulators
US6048873A (en) * 1998-10-01 2000-04-11 Allergan Sales, Inc. Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
US6147224A (en) * 1998-10-01 2000-11-14 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6403638B1 (en) 1998-10-01 2002-06-11 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6326397B1 (en) 1998-11-10 2001-12-04 Hoffman-La Roche Inc. Retinoid antagonists and use thereof
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
WO2001016133A2 (en) 1999-08-27 2001-03-08 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
MXPA02002032A (es) 1999-08-27 2003-05-19 Ligand Pharm Inc Compuestos moduladores del receptor de androgeno y metodos.
JP2003529545A (ja) 1999-09-14 2003-10-07 リガンド・ファーマシューティカルズ・インコーポレイテッド 改善された薬理学的プロファイルを有するｒｘｒモジュレーター
DE60124861T2 (de) 2000-01-21 2007-05-10 Novartis Ag Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6380256B1 (en) 2000-08-29 2002-04-30 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6369225B1 (en) 2000-08-29 2002-04-09 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
ES2316471T3 (es) * 2000-10-02 2009-04-16 F. Hoffmann-La Roche Ag Retinoides para el tratamiento del efisema.
US7348359B2 (en) * 2001-03-14 2008-03-25 Eli Lilly And Company Retinoid X receptor modulators
US6720423B2 (en) * 2002-04-30 2004-04-13 Allergan, Inc. Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
AU2003286243A1 (en) * 2002-11-25 2004-06-18 Amedis Pharmaceuticals Ltd. Silicon compounds
US6759547B1 (en) * 2003-01-14 2004-07-06 Allergan, Inc. 5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity
US7019034B2 (en) * 2003-01-28 2006-03-28 Allergan, Inc. Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
US6759546B1 (en) 2003-02-04 2004-07-06 Allergan, Inc. 3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6884820B2 (en) * 2003-04-03 2005-04-26 Allergan, Inc. 5,6,7,8-tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6734193B1 (en) 2003-06-03 2004-05-11 Allergan, Inc. (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
JP2007501800A (ja) * 2003-08-07 2007-02-01 アラーガン　インコーポレイテッド レチノイドリガンドを用いて悪液質を処置するための方法
US6887896B1 (en) 2003-10-29 2005-05-03 Allergan, Inc. 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
US9050310B2 (en) 2004-06-25 2015-06-09 Minas Theodore Coroneo Treatment of ocular lesions
CA2622600A1 (en) * 2005-10-25 2007-05-03 Werner Bollag Rxr agonists and antagonists, alone or in combination with ppar ligands, in the treatment of metabolic and cardiovascular diseases
US20070185055A1 (en) * 2006-02-06 2007-08-09 Guang Liang Jiang Method for treating cachexia with retinoid ligands
WO2009102789A2 (en) * 2008-02-15 2009-08-20 Wyeth Use of rxr agonists for the treatment of osteroarthritis
JP5877466B2 (ja) * 2012-02-29 2016-03-08 国立大学法人 岡山大学 テルペノイド由来レチノイド化合物
US20160263189A1 (en) 2013-10-23 2016-09-15 Acadia Pharmaceuticals Inc. Treatment of a neurodegenerative disease or disorder
US11045441B2 (en) 2015-10-13 2021-06-29 Wisconsin Alumni Research Foundation Use of retinoic acid and analogs thereof to treat central neural apneas
MX392053B (es) * 2017-09-28 2025-03-21 Johnson & Johnson Consumer Inc Composiciones cosmeticas y metodo para tratar la piel
CA3120970A1 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH651007A5 (de) * 1982-06-24 1985-08-30 Hoffmann La Roche Polyenverbindungen.
EP0170105B1 (en) * 1984-07-07 1990-10-17 Koichi Prof. Dr. Shudo Benzoic acid derivatives
FR2613360B1 (fr) * 1987-04-03 1989-06-09 Oreal Nouveaux derives aromatiques d'acide butyrique, leur procede de preparation et leur utilisation en medecine humaine et veterinaire ainsi qu'en cosmetique
DE69333894D1 (de) * 1992-04-22 2005-12-01 Ligand Pharm Inc Verbindungen mit Retinoid x rezeptorselektivität
US5466861A (en) * 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
DE69324043T2 (de) * 1993-01-11 1999-07-01 Ligand Pharmaceuticals, Inc., San Diego, Calif. Verbindungen mit selektiver wirkung fuer retinoid x rezeptoren, und mittel fuer steuerung fuer durch retinoid x rezeptoren bedingte prozesse
US5344959A (en) * 1993-05-18 1994-09-06 Allergan, Inc. Tetrahydronaphthyl and cyclopropyl substituted 1,3-butadienes having retinoid-like activity

Also Published As

Publication number Publication date
US5801253A (en) 1998-09-01
CY2170B1 (en) 2002-08-23
FI970547L (fi) 1997-02-07
CN1091092C (zh) 2002-09-18
CZ38297A3 (en) 1997-06-11
PL180048B1 (en) 2000-12-29
MX9700778A (es) 1997-05-31
DE69510203T2 (de) 1999-12-23
ATE181052T1 (de) 1999-06-15
AU696501B2 (en) 1998-09-10
NO970580D0 (no) 1997-02-07
DE69510203D1 (de) 1999-07-15
FI112357B (fi) 2003-11-28
CZ288526B6 (cs) 2001-07-11
PL318557A1 (en) 1997-06-23
BR9508985A (pt) 1998-01-06
KR100363545B1 (ko) 2003-02-19
RU2146241C1 (ru) 2000-03-10
NZ292121A (en) 1998-10-28
ES2133798T3 (es) 1999-09-16
EP0775103B1 (en) 1999-06-09
DK0775103T3 (da) 1999-11-15
NO970580L (no) 1997-02-07
GR3031154T3 (en) 1999-12-31
JPH09512830A (ja) 1997-12-22
JP2848964B2 (ja) 1999-01-20
WO1996005165A1 (en) 1996-02-22
TR199500976A2 (tr) 1996-06-21
HUT76839A (en) 1997-11-28
EP0775103A1 (en) 1997-05-28
KR970704663A (ko) 1997-09-06
CA2196197C (en) 2007-04-17
AU3382195A (en) 1996-03-07
FI970547A0 (fi) 1997-02-07
CN1152302A (zh) 1997-06-18
HU218268B (hu) 2000-06-28
CA2196197A1 (en) 1996-02-22

Similar Documents

Publication Publication Date Title
NO307702B1 (no) Retinsyre-X-reseptorligander, anvendelse derav og farmasøytiske preparater
ATE192731T1 (de) Retinoid trienverbindungen und verfahren
ES2124424T3 (es) Azadioxacicloalquenos substituidos y su empleo como fungicidas.
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
DE69530403D1 (de) Analogen des keratinozytenwachstumfaktors
ATE250034T1 (de) Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen
DE69415018D1 (de) Oralanzuwendende flüssige arzneizubereitung enthaltend 2-(4-isobutylphenyl)propionsäure
DE59610175D1 (de) Hydantoinderivate als zwischenprodukte für pharmazeutische wirkstoffe
DE69117375D1 (de) Neue Piperidylether und -thioether als Inhibitoren der Cholesterol-Biosynthese
ES2141978T3 (es) Retinoides triciclicos, metodos para su produccion y uso.
AR004476A1 (es) Compuestos biciclicos, su preparacion y su utilizacion en composiciones farmaceuticas
DE69323191D1 (de) Wasserlösliche retinoide
DE69504050D1 (de) Neue pestizidformulierungen und verfahren zu ihrer herstellung
FR2391208A1 (fr) Thiophenes substitues et compositions pharmaceutiques en contenant
FR2456514A1 (fr) Composition dentaire a base d'or
NO960048L (no) Difluorstaton-analoger
NO974687L (no) Kondenserte <beta>-carboliner
IT1250752B (it) Derivato dell'acido 5-ammino salicilico